Predictors of mortality among multidrug-resistant tuberculosis patients in central Ethiopia: a retrospective follow-up study

Abstract The burden of multidrug-resistant tuberculosis (MDR-TB) related to mortality in resource-poor countries remains high. This study aimed to estimate the incidence and predictors of death among MDR-TB patients in central Ethiopia. A retrospective follow-up study was conducted at three hospitals in the Amhara region on 451 patients receiving treatment for MDR-TB from September 2010 to January 2017. Data were collected from patient registration books, charts and computer databases. Data were fitted to a parametric frailty model and survival was expressed as an adjusted hazard ratio (AHR) with a 95% confidence interval (CI). The median follow-up time of participants was 20 months (interquartile range: 12, 22) and 46 (10.20%) of patients died during this period. The incidence rate of mortality was 7.42 (95% CI 5.56–9.91)/100 person-years. Older age (AHR = 1.04, 95% CI 1.01–1.08), inability to self-care (AHR = 13.71, 95% CI 5.46–34.40), co-morbidity (AHR = 5.74, 95% CI 2.19–15.08), low body mass index (AHR = 4.13, 95% CI 1.02–16.64), acute lung complications (AHR = 4.22, 95% CI 1.66–10.70) and lung consolidation at baseline (AHR = 5.27, 95% CI 1.06–26.18) were independent predictors of mortality. Most of the identified predictor factors of death in this study were considered to be avoidable if the TB programme had provided nutritional support for malnourished patients and ensured a close follow-up of the elderly, and patients with co-morbidities.

[1]  G. Sotgiu,et al.  Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres , 2019, BMC Infectious Diseases.

[2]  K. Tamirat,et al.  Treatment delay and associated factors among adults with drug resistant tuberculosis at treatment initiating centers in the Amhara regional state, Ethiopia , 2019, BMC Infectious Diseases.

[3]  Y. Limenih,et al.  Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia , 2019, BMC Public Health.

[4]  U. Sack,et al.  Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients’ data analysis for outcome and effectiveness of the current regimens , 2018, BMC Infectious Diseases.

[5]  T. Holtz,et al.  Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis , 2018, The Lancet.

[6]  L. Kuonza,et al.  Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013 , 2018, PloS one.

[7]  M. Oo,et al.  Patients with MDR-TB on domiciliary care in programmatic settings in Myanmar: Effect of a support package on preventing early deaths , 2017, PloS one.

[8]  R. Garfein,et al.  Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Swaminathan,et al.  Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. , 2017, Public health action.

[10]  H. Alsdurf,et al.  Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[11]  Tadele Girum,et al.  Survival Status and Treatment Outcome of Multidrug Resistant Tuberculosis (MDR-TB) among Patients Treated in Treatment Initiation Centers (TIC) in South Ethiopia: A Retrospective Cohort Study , 2017 .

[12]  D. Evans,et al.  Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study , 2016, BMC Infectious Diseases.

[13]  C. Contreras,et al.  Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Chong-Jen Yu,et al.  Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis , 2016, Antimicrobial Agents and Chemotherapy.

[15]  L. Fiebig,et al.  Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference? , 2016, Thorax.

[16]  W. Sha,et al.  Efficacy and effect of free treatment on multidrug-resistant tuberculosis , 2015, Experimental and therapeutic medicine.

[17]  J. Andrews,et al.  Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia—an observational cohort study , 2015, Thorax.

[18]  A. Javaid,et al.  Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  Christopher Gilpin,et al.  WHO's new End TB Strategy , 2015, The Lancet.

[20]  E. Houpt,et al.  Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009-2014 , 2015, Tuberculosis and respiratory diseases.

[21]  K. Floyd,et al.  Multidrug-resistant tuberculosis around the world: what progress has been made? , 2014, European Respiratory Journal.

[22]  Sonya S. Shin,et al.  Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Shouyong Tan,et al.  Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation , 2013, PloS one.

[24]  N. Engel The making of a public health problem: multi-drug resistant tuberculosis in India. , 2013, Health policy and planning.

[25]  A. Scheen,et al.  Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. , 2013, Diabetes & metabolism.

[26]  K. Floyd,et al.  Global Epidemiology of Tuberculosis , 2013, Seminars in Respiratory and Critical Care Medicine.

[27]  M. Jiménez-Corona,et al.  Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes , 2012, Thorax.

[28]  K. Fielding,et al.  Association of BMI Category Change with TB Treatment Mortality in HIV-Positive Smear-Negative and Extrapulmonary TB Patients in Myanmar and Zimbabwe , 2012, PloS one.

[29]  M. Casals,et al.  Predictors of Death among Patients Who Completed Tuberculosis Treatment: A Population-Based Cohort Study , 2011, PloS one.

[30]  J. Fitzgerald,et al.  Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis , 2009, PloS one.

[31]  J. Ollgren,et al.  Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study , 2007, BMC public health.

[32]  L. P. Ormerod Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. , 2005, British medical bulletin.

[33]  Y. Amdekar,et al.  Multidrug resistant tuberculosis. , 1998, Indian pediatrics.